Benmelstobart

DRUG9 trials

Conditions

AnlotinibBreast CancerBreast NeoplasmBreast TumorsEarly-stage Breast CancerExtensive-stage Small Cell Lung CancerGastric CancerHER2-negative Breast Cancer

Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

RecruitingNCT05582499

Fudan UniversityBreast Cancer, Breast Neoplasm, Breast Tumors +7

Start: 2022-11-01End: 2028-09-30Target: 716Updated: 2025-08-22

Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

RecruitingNCT06528847

Shanghai Pulmonary Hospital, Shanghai, ChinaNon-Small Cell Lung Cancer

Start: 2024-06-05End: 2030-06-30Target: 62Updated: 2024-07-31

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Not yet recruitingNCT06699498

The First Affiliated Hospital with Nanjing Medical UniversityAnlotinib, Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy +1

Start: 2024-12-03End: 2027-12-01Target: 45Updated: 2024-11-21

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

RecruitingNCT06733051

Sun Yat-sen UniversityNatural Killer T-cell Lymphoma

Start: 2024-01-27End: 2028-12-31Target: 47Updated: 2025-02-10

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

RecruitingNCT06992336

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBreast Cancer

Start: 2025-04-10End: 2036-01-01Target: 411Updated: 2025-05-28

Phase 3

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Not yet recruitingNCT06955325

The First Affiliated Hospital of Guangzhou Medical UniversityNon-Small Cell Lung Cancer

Start: 2025-05-31End: 2035-12-31Target: 270Updated: 2025-05-06

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not yet recruitingNCT07385079

Sun Yat-sen UniversityNasopharyngeal Cancer, Nasopharyngeal Cancinoma (NPC)

Start: 2026-03-01End: 2030-01-01Target: 412Updated: 2026-02-03

Phase 4

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Not yet recruitingNCT06931145

Peking Union Medical College HospitalExtensive-stage Small Cell Lung Cancer

Start: 2025-04-15End: 2027-12-31Target: 50Updated: 2025-04-23

Unknown Phase

The Efficacy and Safety of Benmelstobart for GC/EGC

Not yet recruitingNCT06603974

Xijing HospitalGastric Cancer

Start: 2024-10-16End: 2026-12-26Target: 48Updated: 2024-09-19

Related Papers

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Blood2025-11-03

Abstract GS1-04: HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial

Clinical Cancer Research2025-06-13

Abstract P2-11-06: Neoadjuvant chemotherapy plus camrelizumab vs. chemotherapy in patients with locally advanced immunomodulatory triple-negative breast cancer: a prospective, randomized, open-label, phase 2 trial